Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Unloaded Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently sold shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Vertex Pharmaceuticals stock on August 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 8/14/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 7/24/2026.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX traded down $15.66 during trading hours on Tuesday, reaching $530.46. The company’s stock had a trading volume of 240,478 shares, compared to its average volume of 1,412,194. The company has a market capitalization of $134.63 billion, a P/E ratio of 30.99, a price-to-earnings-growth ratio of 2.37 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a 12 month low of $374.17 and a 12 month high of $560.25. The stock has a 50 day moving average price of $510.43 and a two-hundred day moving average price of $471.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 EPS for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.The firm had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the prior year, the firm posted $4.52 earnings per share. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post 16.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System grew its stake in Vertex Pharmaceuticals by 50,904.3% during the 2nd quarter. California State Teachers Retirement System now owns 190,491,484 shares of the pharmaceutical company’s stock valued at $94,622,835,000 after purchasing an additional 190,118,003 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Vertex Pharmaceuticals in the second quarter worth about $11,975,849,000. Norges Bank acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth about $1,440,149,000. Bank of America Corp DE purchased a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $1,509,651,000. Finally, Legal & General Group Plc acquired a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $928,893,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Duncan McKechnie sold 1,541 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the transaction, the executive vice president directly owned 11,001 shares in the company, valued at $5,709,519. The trade was a 12.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total transaction of $787,485.00. Following the completion of the sale, the executive vice president directly owned 45,321 shares in the company, valued at approximately $23,793,071.79. The trade was a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,719 shares of company stock worth $4,174,147. Company insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on VRTX shares. Stifel Nicolaus set a $500.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 4th. The Goldman Sachs Group set a $653.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, September 1st. Cantor Fitzgerald upped their price target on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Weiss Ratings cut Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 25th. Finally, Canaccord Genuity Group boosted their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $569.52.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.